Statement from Novartis Gene Therapies: OAV301 program for familial ALS caused by SOD1 mutation

lesturner Foundation Blog

Please see summary below from Novartis Gene Therapies on the OAV301 program for familial ALS caused by the SOD1 mutation: Novartis Gene Therapies (formerly AveXis) deeply appreciates the collaboration and support of the amyotrophic lateral sclerosis (ALS) community. Our ALS …

November 2020 Foundation eNews

lesturner Advocacy, Foundation eNews, Home Page, Research & The Les Turner ALS Center, Support Services

Empowering through ALS Education We are excited to launch our new online learning series aimed at empowering our ALS community through the latest information and insights. Educational webinars and interactive Q&A’s covering a diverse array of topics, from telemedicine to …